177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Summary

The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion treatment outcome.

Timeline

Start

2013-05

Primary completion

2022-01-14

Completion

2022-09-19

Publications

• Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I. Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. EJNMMI Res. 2024 Nov 18;14(1):110. doi: 10.1186/s13550-024-01163-w.
• Mileva M, Van Bogaert C, Marin G, Danieli R, Artigas C, Levillain H, Ameye L, Taraji-Schiltz L, Stathopoulos K, Wimana Z, Hendlisz A, Flamen P, Karfis I. 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study. Clin Nucl Med. 2024 Sep 1;49(9):847-853. doi: 10.1097/RLU.0000000000005330. Epub 2024 Jun 19.
• Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987.

Drugs

Indications